• OPEN AN ACCOUNT
Indian Indices
Nifty
19,638.30 114.75
(0.59%)
Sensex
65,828.41 320.09
( 0.49%)
Bank Nifty
44,584.55 283.60
( 0.64%)
Nifty IT
31,784.40 -95.20
( -0.30%)
Global Indices
Nasdaq
13,201.28 108.43
(0.83%)
Dow Jones
33,666.34 116.07
(0.35%)
Hang Seng
17,809.66 436.63
(2.51%)
Nikkei 225
31,857.62 -14.90
(-0.05%)
Forex
USD-INR
83.23 -0.01
(-0.01%)
EUR-INR
87.69 -0.40
(-0.45%)
GBP-INR
101.04 -0.33
(-0.32%)
JPY-INR
0.56 0.00
(-0.24%)

EQUITY - MARKET SCREENER

Sun Pharmaceuticals Industries Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524715
INE044A01036
98.9789412
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SUNPHARMA
65.56
271640.71
EPS(TTM)
Face Value()
Div & Yield %
17.27
1
1.02
 

sun pharmaceuticals industries ltd
Sun Pharma proposes to acquire Taro
May 27,2023
Sun Pharmaceuticals Industries on 26 May 2023 has issued a letter to the Board of Directors of Taro Pharmaceutical Industries, Israel (Taro) with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares in Taro, other than any shares already held by the Company or its affiliates (For a purchase price of $38 per ordinary share) (Proposed Transaction).

The Proposed Transaction to be consummated in the form of a reverse triangular merger under the Israeli Companies Law, 1999 (ICL) and practice. In this context, Purchaser shall form a wholly owned subsidiary (SPV), which shall enter into a merger agreement with Taro, with the SPV merging with and into Taro and Taro surviving the merger transaction. Consequently, Taro shall become a wholly owned subsidiary of Purchaser and be de-listed from NYSE.